Discovery and Characterization of a Cereblon-Based Degrader for PTP1B and TCPTP
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.6c01484 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Zihan Qu und 12 weiteren Autor:innen. Beteiligte Einrichtung: James Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, West Lafayette, Indiana47907, United States. Hauptthemen laut MEDLINE: Protein Tyrosine Phosphatase, Non-Receptor Type 1, Protein Tyrosine Phosphatase, Non-Receptor Type 2, Enzyme Inhibitors, Drug Discovery. Die Arbeit nennt 50 Literaturangaben. Gefördert von: Purdue University, NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Protein tyrosine phosphatase 1B (PTP1B) and T cell protein tyrosine phosphatase (TCPTP) play non-redundant roles in regulating T cell activation and tumor antigen presentation, making them compelling cancer immunotherapy targets. Recent studies have illustrated the viability of concomitant PTP1B/TCPTP degradation as a promising strategy to drug these proteins. Herein, using a phosphonodifluoromethyl phenylalanine (F2Pmp)-based dual PTP1B and TCPTP inhibitor, we report a cereblon (CRBN)-based small molecule degrader X1 targeting both phosphatases with improved potency, selectivity, and plasma exposure after intraperitoneal administration. X1 enhances T cell receptor (TCR) signaling in T cells and IFNγ-mediated JAK1/2-STAT1 activation in tumor cells, promoting surface MHC-I antigen presentation. X1 alone or combined with anti-PD-1 treatment exhibits robust anti-tumor efficacy in a syngeneic tumor model by increasing T cell infiltration and activation. These findings highlight the translational potential of systemic and concomitant targeting of both PTP1B and TCPTP as a promising strategy for cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- James Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, West Lafayette, Indiana47907, United States.
- Department of Biochemistry, Purdue University, West Lafayette, Indiana47907, United States.
- Institute for Cancer Research, Purdue University, West Lafayette, Indiana47907, United States.
- Institute for Drug Discovery, Purdue University, 720 Clinic Drive, West Lafayette, Indiana47907, United States.
ORCID-Profile: Zheng Zhang, Benjamin Babalola, Jingmei Yu, W Andy Tao, Zhong-Yin Zhang
Förderung
- Purdue University
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Qu, Z., Bai, Y., Miao, J., Dong, J., Zhang, Z., Miao, Y., Meke, F. N., Babalola, B., Al-Hindy, M., Huang, B., Yu, J., Tao, W. A., & Zhang, Z. Y. (2026). Discovery and Characterization of a Cereblon-Based Degrader for PTP1B and TCPTP. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c01484
Vancouver
Qu Z, Bai Y, Miao J, Dong J, Zhang Z, Miao Y, et al. Discovery and Characterization of a Cereblon-Based Degrader for PTP1B and TCPTP. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c01484
BibTeX
@article{Qu2026,
author = {Qu, Zihan and Bai, Yunpeng and Miao, Jinmin and Dong, Jiajun and Zhang, Zheng and Miao, Yiming and Meke, Frederick Nguele and Babalola, Benjamin and Al-Hindy, Momen and Huang, Bo and Yu, Jingmei and Tao, W Andy and Zhang, Zhong-Yin},
title = {Discovery and Characterization of a Cereblon-Based Degrader for PTP1B and TCPTP},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.6c01484}
}
EUVIMED